A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus

Pfizer Inc0 个研究点目标入组 25 人开始时间: 2017年1月12日最近更新: 2017年1月16日

适应症

试验速览

暂无简介。

•- Subjects with status epilepticus or repetitive status epilepticus / cluster seizure who have seizures that can be evaluated by investigator's visual observations based on motor symptoms or who have seizures that can be evaluated by EEG.
•- Subjects with status epilepticus accompanied by generalized seizure, partial seizure or secondarily generalized seizure lasting 5 minutes or longer
•- Subjects with repetitive status epilepticus / cluster seizure accompanied by not less than 3 consecutive episodes of generalized seizure, partial seizure or secondarily generalized seizure in 1 hour.
•- Subjects not younger than 3 months (either gender is eligible for the study)
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 15
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 8
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•- Subjects with known or suspected recurrent seizures due to illegal drug or alcohol withdrawal
•- Subjects with known history of hypersensitivity to lorazepam or benzodiazepine
•- Subjects with a known history of benzodiazepine abuse.
•- Subjects currently receiving lorazepam
•- Subjects with angle-closure glaucoma
•- Subjects with myasthenia gravis
•- Subjects with either of aspartate transaminase, alanine transaminase, total bilirubin, blood urea nitrogen, or creatinine at screening visit exceeding 2x the upper limit of normal of the institutional reference value (if the data is available)
•- Subjects with white blood cell count less than 3000/mm3 or neutrophil count less than 1500/mm3 at screening visit (if the data is available)

发起方